本帖最后由 老马 于 2012-1-13 21:20 编辑 2 Q, y0 R+ n$ Y3 z2 Q
, P. C. g4 _3 K5 C; ?1 M# o
爱必妥和阿瓦斯丁的比较
. u8 V' N+ T, V7 n% {2 y
`/ h1 K, v" p5 n+ _- ]& Ohttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
( D( ?! [$ w. o% c0 T9 S
6 S" G I: L! k: D* B
# ?1 ^$ ^9 \4 n* Q5 V4 f
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/) Z; L9 h* f4 g. Q- y
==================================================
# j) u" x- J, z. p+ ^0 q8 OOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
D5 N; q1 N( e; n9 P5 SPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ H u$ S: B0 o- yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% U H' o0 N% w3 N: ]% P% B6 h
|
显身卡
. L+ I/ P- f$ V) ~ q" v
